SHARE NOW
Throughout the Opening Plenary session, a diverse group of experts and thought leaders explored various strategies to address the challenges associated with cell and gene therapy.
The start of Advanced Therapies Week 2024 commenced with the Opening Plenary hosted by Chad Salisbury, Senior Vice President at Precision Medicine Group, sparking ideas and goals for the week ahead.
How are you enjoying this blog post? Let us know your thoughts, here >>
The field of cell and gene therapy aims to develop, manufacture, and commercialize clinical therapies that can significantly improve the lives of patients in need. While these therapies hold vast potential, persistent challenges such as patient access and awareness underscore the importance of collaboration and innovation in overcoming them. The plenary session served as a pivotal session for addressing the challenges and complexities inherent in translating these therapies from the laboratory to the market.
The agenda featured informative presentations, engaging fireside chats, and thought-provoking discussions on the latest trends and regulatory changes shaping the future of this field.
The session began with Susan Nichols, CEO of Propel Biosciences, presenting ‘The Top 10 Events in 2023 for Cell and Gene Therapy,’ followed by a fireside chat featuring Jerrell Shelton, CEO of CryoPort Inc., – with a landmark NASDAQ launch intersecting the section, streamlined live from New York – and discussions on the pivotal role of Women in Advanced Therapies (WIAT), with Lynn Fischer, Founder, and Board Member of Title21 Health Solutions, being featured.
Dr. Celia Witten, Deputy Director of CBER at the FDA, provided attendees with a regulatory update, shedding light on emerging trends and programs facilitating the development of these therapies. Additionally, industry experts such as Dr. Lore Gruenbaum, Vice President of the Therapy Acceleration Program at the Leukemia & Lymphoma Society, and Warner Biddle from Kite Pharma, a Gilead Company, contributed valuable insights to the session.
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
